Dubee, 247 patient HCQ late treatment RCT: 46% lower mortality [p=0.21] and 26% lower combined mortality/intubation [p=0.48] https://c19p.org/dubee
copied to clipboard
Hydroxychloroquine in mild-to-moderate COVID-19: a placebo-controlled double blind trial
et al., Clinical Microbiology and Infection, doi:10.1016/j.cmi.2021.03.005 (preprint 10/21)
Small early terminated late stage (60% on oxygen) RCT in France showing 46% lower mortality.mortality at 28 days relative risk RR 0.54 [0.21-1.42]
combined mortality/intubation at 28 days relative risk RR 0.74 [0.33-1.70]If not stopped early and the same trend continued, statistical significance would be reached on 28 day mortality after ~550 patients (1,300 patients were planned).Mortality results are not provided for subgroups. For the subgroups receiving AZ:No safety concerns were identified. This study has been presented as negative, however the results do not support that conclusion.NCT04325893
combined mortality/intubation at 28 days relative risk RR 0.74 [0.33-1.70]If not stopped early and the same trend continued, statistical significance would be reached on 28 day mortality after ~550 patients (1,300 patients were planned).Mortality results are not provided for subgroups. For the subgroups receiving AZ:No safety concerns were identified. This study has been presented as negative, however the results do not support that conclusion.NCT04325893
|
risk of death at day 28, 46.0% lower, RR 0.54, p = 0.21, treatment 6 of 124 (4.8%), control 11 of 123 (8.9%), NNT 24.
|
|
risk of combined intubation/death at day 28, 26.0% lower, RR 0.74, p = 0.48, treatment 9 of 124 (7.3%), control 12 of 123 (9.8%), NNT 40.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Dubee et al., 10/21/2020, Randomized Controlled Trial, France, Europe, peer-reviewed, median age 77.0, 18 authors, average treatment delay 5.0 days, trial NCT04325893.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.